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Abstract
Objective Dieldrin and aldrin, pesticides widely used until
the 1970s, have been under suspicion of being carcinogenic.
In this study, overall and cause-speciWc mortality was
assessed in a cohort of 570 employees occupationally
exposed to the pesticides dieldrin and aldrin to investigate the
long-term health eVects, in particular carcinogenic eVects.
Methods All of the employees worked in the production
plants between January 1954 and January 1970 and were
followed for cause-speciWc mortality until 30 April 2006.
Based on dieldrin levels in blood samples taken from 343
workers during the exposure period, the total intake of diel-
drin was estimated for each individual subjects in the
cohort. The estimated total intake ranged from 11 to
7,755 mg of dieldrin, with an average of 737 mg.
Results Two hundred and twenty-six workers had died
before 30 April 2006 compared with an expected number of
327.3, giving a standardized mortality ratio (SMR) of 69.0
(95% conWdence interval (CI): 60.3–78.7). Overall cancer
mortality was also signiWcantly lower than expected (SMR:
76.4, 95% CI: 60.8–94.9). Also, none of the speciWc cancer
sites showed a signiWcant excess mortality and no associa-
tion between exposure level and cancer mortality was found.
Conclusion The results from this study support Wndings
from other epidemiological and recent animal studies con-
cluding that dieldrin and aldrin are not likely human carcin-
ogens.
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Introduction
The chlorinated hydrocarbons dieldrin and aldrin were
widely used as pesticides in agriculture from the 1950s up to
the early 1970s (WHO 1989). Later, their use became more
and more restricted to speciWc applications, such as termite
control. They were withdrawn from the market for almost all
uses in the USA in 1974 and subsequently in other countries.
In 1987, production ceased in the last remaining dieldrin and
aldrin producing plant at the Royal Dutch/Shell reWnery in
Pernis, The Netherlands (de Jong 1991).
Dieldrin and aldrin are readily absorbed following inha-
lation, ingestion or skin contact. In the occupational setting,
the latter is thought to be the most important route of expo-
sure. After uptake, aldrin is rapidly converted to dieldrin,
mainly by the P-450 system in the liver. Dieldrin can be
stored in adipose tissue
Since 1962, results from animal studies (Davis and
Fitzhugh 1962) have spurred concerns that dieldrin and ald-
rin may be human carcinogens as well. The EPA published
a report on the assessment of the human cancer risk of
dieldrin and aldrin in 1987 (EPA 1987). In this report,
dieldrin and aldrin were classiWed as probable human
carcinogens. This classiWcation was mainly based on evi-
dence of hepatocarcinogenesis in mice. The International
Agency for Research on Cancer classiWed the evidence for
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218 Int Arch Occup Environ Health (2009) 82:217–225carcinogenicity in humans as inadequate and animal carcin-
ogenicity as limited (IARC 1987). However, since the EPA
assessment of human cancer risk, there is accumulating evi-
dence which has called into question the value of mouse
liver tumors as a reliable predictor of carcinogenic potential
in humans. Dieldrin-induced oxidative stress or its sequelae
apparently result in modulation of gene expression that
favors expansion of initiated mouse, but not rat, liver cells;
thus, dieldrin acts as a nongenotoxic promoter/accelerator
of background liver tumorigenesis in the mouse (Stevenson
et al. 1999). Recent animal studies provide a possible
explanation for the speciWc mouse hepatocarcinogenity of
aldrin/dieldrin (Stevenson et al. 1999, 1995; Kolaja et al.
1996). More recently, Kamendulis et al. (2001) further
unraveled the mechanism and reported that high level diel-
drin exposure of mice was accompanied by increased
nuclear ploidy and mitosis.
Dieldrin and aldrin were produced at two sites and were
formulated in many others. Ditraglia et al. (1981) studied
an organochlorine manufacturing plant in Colorado, USA,
following 1,155 workers from 1951 to 1977. In the group of
dieldrin and aldrin workers, a signiWcant increase in pneu-
monia and other respiratory diseases was observed. Total
cancer mortality was lower than expected. Small and statis-
tically insigniWcant increases were observed for liver, rec-
tum, esophageal and lymphohaematopoietic neoplasms.
The investigators did not regard these Wndings as eVects of
the occupational exposures and they recommended further
monitoring of the cohort.
In an update of this cohort by Brown, in which the fol-
low-up was extended to 31 December 1987, a statistically
signiWcant excess mortality from liver cancer was noted (5
observed deaths vs. 1.3 expected) (Brown 1992). This
cohort study was later expanded and updated until 31
December 1990 by Amoateng-Adjepong et al. (1995). The
study conducted by Amoateng-Adjepong includes all data
collected in the earlier studies on cohorts investigated by
Ditraglia and Brown. Therefore, the results of the Amoat-
eng-Adjepong study provide the most complete picture of
the mortality experience of the workers of the Colorado
plant. Total mortality and all cancer mortality were within
the expected range. None of the cause-speciWc standardized
mortality ratios (SMRs) were signiWcantly elevated. During
the extended follow-up period between 31 December 1987
and 13 December 1990 no additional deaths from liver can-
cer were noted.
The second manufacturing plant that has been subjected
to extensive epidemiological investigation is the Shell plant
at Pernis, near Rotterdam, The Netherlands. Five hundred
and seventy workers of this plant, employed between 1954
and 1970, have been followed through 2001 (de Jong et al.
1997; Swaen et al. 2002). The cause-speciWc mortality pat-
terns of these workers were not diVerent from the expected
patterns. A statistically signiWcant increase in rectal cancer
was seen: however, it was inversely related to dose. Based
on three cases, liver cancer was non-signiWcantly increased
in the two lower dose groups, but there were no cases in the
highest exposed group (Swaen et al. 2002).
Apart from these two retrospective cohort studies on
workers from these production plants, little other epidemio-
logical work has been done on aldrin or dieldrin. Schroeder
et al. reported an association between certain subtypes of
non-Hodgkin lymphoma and the reported use of dieldrin by
farmers (Schroeder et al. 2001). Hoyer et al. (2000), in a
Danish study on the survival of breast cancer patients,
reported an inverse association between survival and diel-
drin serum levels in blood. Recently, Purdue et al. reported a
signiWcant positive association between self-reported diel-
drin exposure and lung cancer and a signiWcant inverse rela-
tion between self-reported aldrin exposure and colon cancer
(Purdue et al. 2007). However, the overall results of these
three studies seem inconsistent and none of the reported
Wndings have been replicated. For example, a second case/
control study of breast cancer cases and organochlorine
traces did not Wnd a relationship between breast cancer and
dieldrin concentrations in serum (Ward et al. 2000).
As mentioned earlier, the Pernis plant is one of the few
plants that produced dieldrin and aldrin and has the longest
record of producing these substances. Therefore the cohort
of 570 workers employed at this plant provides a unique
opportunity to assess the potential long-term health risk in a
population with a high occupational exposure to dieldrin
and aldrin. Furthermore, it is the only cohort of its kind
where detailed exposure assessment by industrial hygiene
data and matching biological monitoring data is available.
This exposure assessment was published in detail by de
Jong (1991). This study provided data on individual expo-
sures over the years of employment for all subjects who had
been employed in the Pernis plants between 1954 (when
dieldrin and aldrin production and formulation in this plant
began) and 1970. Mortality data from this cohort have been
updated and previously assessed by de Jong et al. (1997)
and Swaen et al. (2002). With this Wnal update, data are
made available with a mean follow-up of 38 years (ranges
from 1 to 52 years). Therefore, this update provides a
unique opportunity to assess the potential eVects on overall
and cause-speciWc mortality from dieldrin and aldrin with
an extended latency period.
Methods
Study population
The population consisted of 570 male employees who
worked for at least 1 year in one of the units of the pesticide123
Int Arch Occup Environ Health (2009) 82:217–225 219production plants at Pernis between 1 January 1954 and 1
January 1970. The production plant consisted mainly of an
intermediates production plant, an aldrin production plant,
a dieldrin production plant and a formulation plant where
the Wnal products were mixed and diluted in such a way that
they became suitable for agricultural use by customers.
Static air sampling in 1958, 1959 and 1960 indicated that
the air concentrations in the plant were usually a factor of
5–10 below the threshold limit value as a time weighted
average (TLV–TWA) level of 0.25 mg/m3. However, some
tasks, such as drum Wlling, resulted in exposure concentra-
tions as high as 4 mg/m3.
Because of the importance of skin contact to absorption,
ambient air measurements are not thought to give an appro-
priate reXection of exposure. Therefore, estimations of total
intake by means of biomonitoring data are regarded as far
superior to ambient air monitoring within the given context.
An extensive set of biomonitoring data on these workers is
available. In the 1960s, several industrial hygiene and bio-
logical monitoring programs had been conducted. During
the monitoring programs, levels of dieldrin in the blood of
workers were determined. Since aldrin is rapidly converted
to dieldrin in the body, aldrin levels in blood were not mon-
itored. Between 1963 and 1965, a methanol/hexane extrac-
tion method was used. Later, this method was replaced by
an acetone/hexane method, which is nearly 100% accurate.
The determination of dieldrin was carried out by gas–liquid
chromatography with electron capture detection (de Jong
1991). The biomonitoring was common practice between
1963 and 1970 and varied between every 3 months and
once a year.
For 343 of 570 subjects, multiple dieldrin blood mea-
surements are available. From these biomonitoring data, the
total intake of dieldrin was calculated using the method
described in detail by de Jong (1991). In summary, the
association between intake and the resulting blood concen-
tration was studied earlier by means of a human volunteer
study in which three groups of volunteers ingested doses of
10, 50 or 211 mg of dieldrin daily. The relationship
between intake and dieldrin in blood was best described by
the formula: C = A ¡ Be¡k(t1 ¡ t0) in which “C” is the diel-
drin concentration in blood (in g/ml) attained at time t1
under the assumption of a constant daily intake from time
t0. “A” represents the dieldrin concentration in the blood at
equilibrium and “B” is the background concentration in the
blood originating from other sources, for instance, from
food. “K” is the Wrst order rate constant for elimination of
dieldrin from the human body. The biological half-life of
dieldrin was calculated to be 267 days (Versteeg and Jager
1973). Assuming a stable exposure rate the total intake of
dieldrin and aldrin for each worker was estimated based on
the biomonitoring data. For the workers with no biomoni-
toring data, estimates of total intake were made using the
biomonitoring data of coworkers with the same job, work-
place and time interval.
Total intake of dieldrin and aldrin ranged from 11 to
7,755 mg, accumulated during their work at the plants up to
1970. In 1970, several major improvements were made in
the working environment and processes, and exposure to
dieldrin and aldrin was greatly reduced. The eVects of these
improvements have been demonstrated by decreases in
dieldrin levels in blood. Using the individual total dieldrin
and aldrin intake estimates, the population was stratiWed
into three groups (with 190 workers in each group): low,
moderate and high levels of total intake. The arithmetic
mean of total intake in the low group (n = 190) was 270 mg
of dieldrin and aldrin. In the moderate intake group
(n = 190) the mean was 540 mg, and in the high group
(n = 190) it was 750 mg. Alongside the stratiWcation of the
exposed workers into the three subgroups, we conducted
analyses for the speciWc jobs in the plants. We identiWed
four diVerent jobs, namely assistant operator (n = 165),
maintenance worker (n = 83), operator (n = 302) and super-
visor (n = 20). It was estimated that the highest exposures
occurred in assistant operators and operators of the formu-
lation plant and in the assistant operators of the dieldrin and
aldrin production plants.
Follow-up
The total cohort was followed for mortality until 30 April
2006. By means of the Dutch Municipal Population Regis-
tries, information was collected on the vital status of each
study subject. For deceased workers, the underlying cause
of death was obtained from the Central Bureau of Statistics.
Ascertainment of vital status and causes of death
The procedures that were applied to obtain the vital status
and the causes of death were similar to the previous study.
The municipal population registries (about 460 in The
Netherlands in 2006) were requested to provide informa-
tion on the whereabouts of the workers that were included
in this study. For workers who had moved from one munic-
ipality to another, the new municipality was requested to
provide vital status information on that particular worker.
This process was repeated after each notiWcation that a per-
son had moved. In this way, all of the 570 ex-workers were
traced.
Another route for identiWcation of vital status was by
consulting a special registry for persons who had left The
Netherlands by means of emigration. It was noted that quite
a lot of people who had emigrated during some time in their
lives returned to The Netherlands after retirement. Check-
ing the data provided by this registry revealed additional
information on former workers. As a result, these persons123
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son years were calculated and added to the total person
years of follow-up. (More detailed information on vital sta-
tus is shown in Table 1.)
In the last step in identifying the individual causes of
death for all the deceased former employers death certiW-
cate data was retrieved from the Central Bureau of Statis-
tics (CBS). The CBS receives a copy of all Dutch death
certiWcates after a person’s death. After the receipt of the
death certiWcates, the causes of death are coded by trained
nosologists and computerized to accumulate the annual
vital statistics, which are presented by causes of death. For
all deceased workers, the cause of death was identiWed in
this database.
Statistics
The observed cause-speciWc mortality of the cohort was
compared with the expected number based on age and time
interval cause-speciWc mortality rates of the total male
Dutch population. SMRs were calculated by dividing the
observed numbers of deaths by the expected numbers
(£100), and appropriate 95% conWdence limits (CI) were
calculated with an exact method based on the Poisson dis-
tribution. This was done using the SAS Macro as described
by Daly (1992). Since employees were classiWed into three
groups of cumulative exposure (total intake), the expected
numbers of deaths were calculated based on the person-
years of observation accumulated after termination of expo-
sure as described by Swaen and Volovics (1987).
Results
As of 30 April 2006, 226 workers had died, adding 55
deaths to the earlier follow-up (see Table 1). Nine persons
were lost to follow up, as they were not registered by the
communal personal administration any more. The total
number of person-years of observation time was 21,702.
The 226 total observed deaths were signiWcantly lower than
the expected number of 327.3, resulting in a SMR of 69.0
(95% CI: 60.3–78.7). A detailed overview of total and
cause speciWc mortality can be found in Table 2. For all
four categories of major causes of death, the number of
observed deaths was lower than the expected and none of
the cause-speciWc SMRs was signiWcantly elevated. In fact,
nearly all cause-speciWc SMRs were below 100. The SMR
for liver and biliary passages cancer, the cancer of primary
interest based on the mouse data, was 216.1 (95% CI: 58.9–
553.9) based on four observed cases.
To assess a potential relationship with cumulative expo-
sure, an exposure level stratiWed analysis was performed
(Table 2) using three groups with 190 workers per group.
The low-intake group had a cumulative intake between 11
and 201 mg of aldrin and/or dieldrin. The intake of the
moderate group ranged from 203 to 732 mg. Workers in the
high-intake group all had estimated intakes ranging from
737 to 7,755 mg, with an arithmetic mean of 1,704 mg. In
all the three dose groups, the mortality for all causes was
signiWcantly lower than the general population of The
Netherlands with SMRs of 75.1, (95% CI: 57.2–96.9), 72.1
(95% CI: 57.0–90.0), and 67.0 (95% CI: 53.8–82.4) for the
low, moderate and high dose groups, respectively. When
looking at the overall mortality due to neoplasms, all SMRs
were the same or below 100 with a downward trend with
increasing cumulative exposure. For the high-intake group,
the mortality for neoplasms was signiWcantly lower than the
Dutch general population (SMR = 66.2, 95% CI: 44.0–
95.6). With respect to liver and skin malignancies, there
were non-statistical excesses in the total group
(SMR = 216.1, 95% CI: 58.9–553.9 and SMR = 302.4,
95% CI: 62.4–883.8, respectively), but no deaths were
observed in the high-intake group. For rectal cancer, a non-
statistical excess in the total group was observed
(SMR = 214.8, 95% CI: 78.8–467.6), a small and non-sig-
niWcant excess mortality in the high-intake group was also
observed (SMR = 175.6, 95% CI: 21.3–634.3), but no clear
trend with exposure was observed. Similar pattern of no
trend with exposure was seen for oesophagus cancer. The
overall mortality risk for bladder cancer was decreased
Table 1 Vital status ascertain-
ment on 1 May 2006 for 570 
workers exposed the dieldrin 
and aldrin between 1 January 
1954 and 1 January 1970
Vital status at end 
date of follow-up
Follow-up 
until 1 January 1993
Follow-up 
until 1 January 2001
Follow-up 
until 1 May 2006
N (%) N (%) N (%)
Alive 402 70.5 335 58.8 297 52.1
Emigrated 35 6.2 47 8.2 38 6.7
Lost to follow-up 15 2.6 17 3.0 9 1.6




Total group 570 100 570 100 570 100123
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































222 Int Arch Occup Environ Health (2009) 82:217–225(SMR = 79.7, 95% CI: 16.4–232.8) although it was slightly
elevated, albeit non-signiWcant, in the highest intake group
(SMR = 127.9, 95% CI: 15.5–461.9).
The sub classiWcation by job held (Table 3) revealed a
signiWcantly lowered mortality from lung cancer (SMR:
43.4, 95% CI: 19.8–82.3) and signiWcantly elevated number
of skin cancers (SMR: 575.8, 95% CI: 118.8–1,682.8) in
the operators group.
Discussion
After 52 years of follow up, this cohort of 570 workers
exposed to dieldrin and aldrin does not demonstrate any
excess cancer mortality risk that could be related to exposure.
For overall and most speciWc cancer types, the observed
numbers of deaths were lower than expected based on the
cause-speciWc mortality rates of the total male Dutch popula-
tion. The only signiWcantly elevated SMR (skin cancer in
operators) is most likely a chance Wnding that can be attrib-
uted to the number of statistical comparisons performed in
this study. There were no additional cases since the previous
update (Swaen et al. 2002). None of the other epidemiologi-
cal or animal studies available report a similar Wnding.
When considering potential exposure to dieldrin and ald-
rin, mortality from liver cancer is of interest based on
mouse studies. In two updates of a study Wrst conducted by
Ditraglia et al. (1981), the investigators found an increase
in deaths from cancer of the liver and biliary passages (de
Jong et al. 1997; Swaen et al. 2002). The current study
found an increase, although statistically insigniWcant, of
deaths from cancer of the liver and biliary passages but no
increasing dose–response relationship. There were four
deaths, two in the lowest exposure group and two in the
moderate exposure group, but none of the deaths occurred
in the highest exposure group. So this breakdown by intake
does not indicate statistically signiWcantly increased SMRs
and does not suggest an increasing cancer risk with increas-
ing dose. Of the two deaths in the moderate exposure
group, one was primary liver carcinoma and the other was
from cancer of the gall bladder. The individual with liver
cancer worked at Pernis for about 2 years after having
worked as a Wsherman and sailor for the previous 40 years.
This individual had a medical history suggestive of a non-
occupational risk factor for liver cancer. These results make
a causal association of liver and biliary passages cancer
with aldrin or dieldrin unlikely.
It is to be noted that the observed number of deaths from
cancer of the rectum was statistically greater than expected
in the previous two studies of this cohort, although none
showed a dose-response relation. Between 1993 and 2006,
there was no new rectal cancer death, and the mortality risk
(i.e., SMR) has been decreased from 390 (95% CI: 140–850)
in the original study (de Jong et al. 1997) to 300 (95% CI:
109–649) in the 2001 update study (Swaen et al. 2002), and
to 216 (95% CI: 59–554) in the current study. In addition,
no deaths were observed in the high intake group.
This cohort of workers provides us with one of the few
possibilities to evaluate the long-term health eVects of
relatively high dieldrin/aldrin exposure levels in a human
population. Moreover, this study also incorporated data on
estimated intake of dieldrin for individual cohort members,
based on blood samples from 343 workers during the
period in which exposure had occurred. Cumulative intake
of the 570 study subjects varied between 11 and 7,755 mg,
with an average of 737 mg. It is estimated that over 75% of
the cohort had dieldrin exposure levels that exceeded the
assumed human equivalent dose rate corresponding to the
lowest positive dose rate for female mice in a cancer bioas-
say in which the incidence of liver tumors had doubled.
Sielken et al. (1999), based on an earlier study of this
cohort, have reported a cancer risk assessment for dieldrin
and aldrin. The overall mortality for cancer of that study
was slightly lower than the Dutch general population (46
observed deaths with an SMR of 96.8, 95% CI = 71–129).
When examining cancer risks by levels of exposure, the
SMRs were 118.9 (95% CI=63.2–203.3), 102.1 (95%
CI=58.3–165.8) and 81.4 (95% CI=47.4–130.3) for the
low, moderate and high exposure groups, respectively.
Based on lifetime average daily dose in g/kg body weight/
day of dieldrin and aldrin, the study found that there were
not an increase in cancer risks of 10¡6 at lifetime average
dose of 0.0000625 or 10¡4 at 0.00625 as would be esti-
mated using US Environmental Protection Agency’s upper
bound on cancer potency based on mouse liver tumors. In
fact, there was no observed increase in cancer risk in these
workers at doses as large as 2 g/(kg day). Since the mor-
tality pattern of the current study is the same as that
reported earlier, results of cancer potency assessment from
the previous analysis would apply to this study, probably
with a narrower conWdence interval.
It is not likely that bias with respect to ascertainment and
coding of the causes of death may have aVected the study
outcome. Information regarding the causes of death was
collected from the CBS where the causes of death were
coded at the time of death by trained nosologists who were
unaware of our study and were unaware of which persons
were or were not a member of the cohort. Equally, informa-
tion regarding exposure, including the calculation of total
intake, was performed without any knowledge of the vital
status and cause of death if applicable. Also, the number of
subjects lost to follow-up in this study is low when consid-
ering the long period of follow up. This follow up has even
been able to trace some of the respondents, which were
lost-to-follow up in previous updates, due to remigration
and improvements in the registries.123


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































224 Int Arch Occup Environ Health (2009) 82:217–225A limitation of the study is its relatively small sample
size. However, the power of a retrospective cohort study
depends on the number of expected events of interest, in
this case cancer deaths, in combination with the expected
magnitude of the eVect of the exposure. In fact, given an 
level of 0.05 and 80% power, the sample size (i.e. person
years) of this study is capable of detecting at least a 34%
increase risk in cancer (Armstrong 1987), if such a risk did
exist. However, as none of the cancers revealed a signiW-
cant excess mortality risk and no exposure response rela-
tionship was observed for any of the cancer sites, this
follow up study supports the conclusion that aldrin/dieldrin
exposure does not lead to an increased cancer risk in man.
This cohort is one of two cohorts that have been
involved in the production of dieldrin and aldrin in the
world. Their exposure has been accurately documented and
as such provides an excellent opportunity to learn more
about the possible long-term eVects of these pesticides. In
addition, the time window of observation is 52 years,
between 1 January 1954 and 30 April 2006, which is a suY-
cient latency period. In fact, all exposed workers were
employed before 1 January 1970 and 52.3% before 1
January 1960. Our Wndings add to the growing body of
evidence, provided by both epidemiological studies
(Amoateng-Adjepong et al. 1995; Ward et al. 2000) and
recent animal studies (Stevenson et al. 1999; Kamendulis
et al. 2001), showing a lack of an association between ald-
rin/dieldrin exposure and cancer mortality.
The overall mortality of this occupational cohort remains
signiWcantly lower than the general male population of the
Netherlands, after 52 years of follow-up. This is commonly
referred to as the healthy worker eVect (Checkoway et al.
1989), which can be attributed to a number of factors (Li and
Sung 1999). However, it is somewhat unexpected to Wnd that
the overall SMR decreased compared to the previous update
while the majority of the cohort has reached their retirement
age. One explanation is that the cohort members of this pres-
ent study are healthier. The lack of complete ascertainment
of death is also a possible reason, however, it is not likely
since the lost to follow-up was extremely low, only 1.6%.
Furthermore, as 70–80% of the reference population is also
working, the Wnding of such a decreased risk is less likely to
be totally explained by the healthy worker eVect. A similar
observation has been reported by others; the SMR was 74.7
in the original study (Enterline et al. 1990) but decreased to
60.7 in an additional 10-year follow-up (Tsai et al. 1996).
A longer follow-up would provide more precise risk esti-
mates and a better understanding of the relationship
between exposures and disease. However, a recent study
has suggested that increasing follow-up could decrease the
risk estimate of occupational cohorts (Silver et al. 2002).
Some also postulated that risk estimates could be “diluted”
with increasing follow-up if the exposure acts as a promoter
rather than an initiator (Lamm et al. 1989). Nevertheless,
the potential negative impact of extending follow-up has
not been well understood and requires further studies.
In conclusion, our study supports the results of other
extensive epidemiological studies of workers exposed to
dieldrin and aldrin. That is that there is no evidence of an
increased mortality risk for cancer of any particular type as
a result of exposure to aldrin or dieldrin.
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